Loading…
Loading…
See exactly how PJP's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for PJP and 80,000+ other tickers.
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. The underlying index is composed of common stocks of 30 U.S. pharmaceutical companies. These companies are engaged principally in the research, development, manufacture, sale or distribution of pharmaceuticals and drugs of all types. The fund is non-diversified.
Invesco's concentrated 30-stock pharma fund delivered 43.1% returns last year, but iShares' broader 100-holding portfolio costs less and offers wider sector exposure.
Launched on June 23, 2005, the Invesco Pharmaceuticals ETF (PJP) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Pharma segment of the equity market.
Bank of America Corp DE raised its stake in shares of Invesco Pharmaceuticals ETF (NYSEARCA:PJP) by 234.0% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 74,458 shares of the company's stock after purchasing an additional 52,165 shares during the quarter.
Fidelity MSCI Health Care Index ETF (FHLC) offers a significantly lower expense ratio and a higher dividend yield than the Invesco Pharmaceuticals ETF (PJP). PJP provides a concentrated portfolio of just over 30 pharmaceutical stocks, while FHLC diversifies across more than 300 holdings.
The State Street SPDR S&P Pharmaceuticals ETF offers a significantly lower expense ratio of 0.35% compared to the Invesco Pharmaceuticals ETF. The Invesco Pharmaceuticals ETF provides a more concentrated portfolio of 29 stocks and lower price volatility as measured by beta.